The Antibacterial Resistance Leadership Group will begin a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial to examine safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa.